Corvus Pharmaceuticals Inc (FRA:C17)
€ 8.11 -0.01 (-0.12%) Market Cap: 547.60 Mil Enterprise Value: 504.48 Mil PE Ratio: 0 PB Ratio: 10.74 GF Score: 22/100

Corvus Pharmaceuticals Inc ASCO Investor and Analyst Reception Transcript

Jun 02, 2019 / 11:00PM GMT
Richard A. Miller
Corvus Pharmaceuticals, Inc. - Co-Founder, President, CEO & Chairman of the Board

All right. I think you can unmute me now. Ready to go? Great. First of all, thank you very much, all of you, for attending. This is a great turnout on a Sunday night. At least I think it's Sunday. I'm not sure what day it is. I've lost track, but we appreciate you all coming. We have, I think, a very interesting agenda for you tonight.

As you know, we presented, I think, a really beautiful paper this morning, presented by Dr. Luke, who's joining us this evening. Dr. Luke, of course, did this work while at the University of Chicago, but he's recently moved to the University of Pittsburgh. So if you're a Steelers' fan, you'll be happy.

The paper today that Dr. Luke presented makes me extremely proud of the work of our collaborators and the work of people at our company. For those of you who were there, it is -- and I have been doing this for like 30 years, it was a great, great demonstration of a really nicely conducted Phase I study that had beautiful safety, early assessments of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot